Mario Silva

Mario Silva

Auto-generated profile, based on publicly available information

Mario Silva

Department of Medicine and Surgery (DiMeC), Scienze Radiologiche, University of Parma, Parma, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
UPUgo Pastorino
Ugo Pastorino
MSM. Silva
M. Silva
SSS. Sestini
S. Sestini
FSF. Sabia
F. Sabia
MBMattia Boeri
Mattia Boeri
AMA. Marchianò
A. Marchianò
The National Lung Screening Trial showed that lung cancer (LC) screening by three annual rounds of low-dose computed tomography (LDCT) reduces LC mortality. We evaluated the benefit of prolonged LDCT screening beyond 5 years, and its impact on overall and LC specific mortality at 10 years. The Multicentric Italian Lung Detection (MILD) trial prospectively randomized 4099 participants, to a screening arm (n = 2376), with further randomization to annual (n = 1190) or biennial (n = 1186) LDCT for a median period of 6 years, or control arm (n = 1723) without intervention. Between 2005 and 2018, 39 293 person-years of follow-up were accumulated. The primary outcomes were 10-year overall and LC specific mortality. Landmark analysis was used to test the long-term effect of LC screening, beyond 5 years by exclusion of LCs and deaths that occurred in the first 5 years. The LDCT arm showed a 39% reduced risk of LC mortality at 10 years [hazard ratio (HR) 0.61; 95% confidence interval (CI) 0.39–0.95], compared with control arm, and a 20% reduction of overall mortality (HR 0.80; 95% CI 0.62–1.03). LDCT benefit improved beyond the 5th year of screening, with a 58% reduced risk of LC mortality (HR 0.42; 95% CI 0.22–0.79), and 32% reduction of overall mortality (HR 0.68; 95% CI 0.49–0.94). The MILD trial provides additional evidence that prolonged screening beyond 5 years can enhance the benefit of early detection and achieve a greater overall and LC mortality reduction compared with NLST trial. NCT02837809.

1 August 2020 in Radiology
Verified
Journal Article
Closed access
DCDavide Colombi
Davide Colombi
FBFlavio C. Bodini
Flavio C. Bodini
MPMarcello Petrini
Marcello Petrini
GMGabriele Maffi
Gabriele Maffi
NMNicola Morelli
Nicola Morelli
EMEmanuele Michieletti
Emanuele Michieletti
Background Computed tomography (CT) of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease depicts the extent of lung involvement in COVID-19 pneumonia. Purpose The a...

1 November 2018 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
SWSimon L F Walsh
Simon L F Walsh
LCLucio Calandriello
Lucio Calandriello
MSMario Silva
Mario Silva
NSNicola Sverzellati
Nicola Sverzellati

1 October 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
SWSimon L. F. Walsh
Simon L. F. Walsh
JMJohn Mackintosh
John Mackintosh
LCLucio Calandriello
Lucio Calandriello
MSMario Silva
Mario Silva
NSNicola Sverzellati
Nicola Sverzellati
TCTamera J. Corte
Tamera J. Corte
Rationale: Reliable outcome prediction in patients with fibrotic lung disease using baseline high-resolution computed tomography (HRCT) data remains challenging. Objectives: To evaluate the prognostic accuracy of a deep learning algorithm (SOFIA [Systematic Objective Fibrotic Imaging Analysis Algorithm]), trained and validated in the identification of usual interstitial pneumonia (UIP)-like features on HRCT (UIP probability), in a large cohort of well-characterized patients with progressive fibrotic lung disease drawn from a national registry. Methods: SOFIA and radiologist UIP probabilities were converted to Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED)-based UIP probability categories (UIP not included in the differential, 0–4%; low probability of UIP, 5–29%; intermediate probability of UIP, 30–69%; high probability of UIP, 70–94%; and pathognomonic for UIP, 95–100%), and their prognostic utility was assessed using Cox proportional hazards modeling. Measurements and Main Results: In multivariable analysis adjusting for age, sex, guideline-based radiologic diagnosis, anddisease severity (using total interstitial lung disease [ILD] extent on HRCT, percent predicted FVC, DlCO, or the composite physiologic index), only SOFIA UIP probability PIOPED categories predicted survival. SOFIA-PIOPED UIP probability categories remained prognostically significant in patients considered indeterminate (n = 83) by expert radiologist consensus (hazard ratio, 1.73; P < 0.0001; 95% confidence interval, 1.40–2.14). In patients undergoing surgical lung biopsy (n = 86), after adjusting for guideline-based histologic pattern and total ILD extent on HRCT, only SOFIA-PIOPED probabilities were predictive of mortality (hazard ratio, 1.75; P < 0.0001; 95% confidence interval, 1.37–2.25). Conclusions: Deep learning–based UIP probability on HRCT provides enhanced outcome prediction in patients with progressive fibrotic lung disease when compared with expert radiologist evaluation or guideline-based histologic pattern. In principle, this tool may be useful in multidisciplinary characterization of fibrotic lung disease. The utility of this technology as a decision support system when ILD expertise is unavailable requires further investigation.

11 February 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
NSNicola Sverzellati
Nicola Sverzellati
MSM. Silva
M. Silva
GCG. Calareso
G. Calareso
CGCarlotta Galeone
Carlotta Galeone
AMA. Marchianò
A. Marchianò
UPUgo Pastorino
Ugo Pastorino

1 September 2019 in European Journal of Cancer
Verified
Journal Article
Open access
UPUgo Pastorino
Ugo Pastorino
NSN. Sverzellati
N. Sverzellati
SSS. Sestini
S. Sestini
MSM. Silva
M. Silva
FSF. Sabia
F. Sabia
AMA. Marchianò
A. Marchianò
The Multicentric Italian Lung Detection (MILD) trial demonstrated that prolonged low-dose computed tomography (LDCT) screening could achieve a 39% reduction in lung cancer (LC) mortality. We have here evaluated the long-term results of annual vs. biennial LDCT and the impact of screening intensity on overall and LC-specific mortality at 10 years. Between 2005 and 2018, the MILD trial prospectively randomised the 2376 screening arm participants to annual (n = 1190) or biennial (n = 1186) LDCT, for a median screening period of 6.2 years and 23,083 person-years of follow-up. The primary outcomes were 10-year overall and LC-specific mortality, and the secondary end-points were the frequency of advanced-stage and interval LCs. The biennial LDCT arm showed a similar overall mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.57-1.12) and LC-specific mortality at 10 years (HR 1.10, 95% CI 0.59-2.05), as compared with the annual LDCT arm. Biennial screening saved 44% of follow-up LDCTs in subjects with negative baseline LDCT, and 38% of LDCTs in all participants, with no increase in the occurrence of stage II-IV or interval LCs. The MILD trial provides original evidence that prolonged screening beyond five years with biennial LDCT can achieve an LC mortality reduction comparable to annual LDCT, in subjects with a negative baseline examination.